Capricor Therapeutics, Inc.
CAPR
$8.64
-$0.42-4.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -52.08% | -50.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -52.08% | -50.68% |
| Cost of Revenue | 48.14% | 60.80% | 69.02% | 67.30% | 54.51% |
| Gross Profit | -84.92% | -129.88% | -204.91% | -192.63% | -228.41% |
| SG&A Expenses | 81.91% | 60.22% | 59.34% | 56.42% | 43.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.71% | 60.67% | 66.80% | 64.73% | 51.86% |
| Operating Income | -84.12% | -109.37% | -154.07% | -139.79% | -144.66% |
| Income Before Tax | -84.95% | -108.11% | -159.58% | -140.34% | -150.38% |
| Income Tax Expenses | 0.00% | 100.00% | 100.00% | -- | -- |
| Earnings from Continuing Operations | -84.94% | -108.11% | -159.58% | -140.35% | -150.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.94% | -108.11% | -159.58% | -140.35% | -150.39% |
| EBIT | -84.12% | -109.37% | -154.07% | -139.79% | -144.66% |
| EBITDA | -85.38% | -111.38% | -158.28% | -144.08% | -149.83% |
| EPS Basic | -49.27% | -62.97% | -88.48% | -69.35% | -76.39% |
| Normalized Basic EPS | -49.72% | -63.53% | -88.60% | -68.79% | -75.81% |
| EPS Diluted | -49.27% | -62.97% | -88.48% | -69.35% | -76.39% |
| Normalized Diluted EPS | -49.72% | -63.53% | -88.60% | -68.79% | -75.81% |
| Average Basic Shares Outstanding | 24.26% | 27.49% | 32.04% | 43.02% | 41.17% |
| Average Diluted Shares Outstanding | 24.26% | 27.49% | 32.04% | 43.02% | 41.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |